Clinical trial
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum…
NCT00350948 · Telik, Industry · Terminated
Key facts
| NCT number | NCT00350948 |
|---|---|
| Title | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer |
| Official title | Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5) |
| Acronym | ASSIST-5 |
| Lead sponsor | Telik, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | Telcyta, Liposomal Doxorubicin |
| Enrollment | 244 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 11, 2006 |
| Last update posted | Nov 27, 2013 |
| Countries | Belgium, Brazil, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: